MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans - no need for translation

Br J Pharmacol. 2012 Jul;166(5):1518-20; discussion 1521-2. doi: 10.1111/j.1476-5381.2012.01941.x.

Abstract

In this issue of the BJP, Green et al. suggest that animal data could not be used to predict the adverse effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans and that MDMA did not produce 5-HT neurotoxicity in the human brain. This proposal was, however, not accompanied by a review of the empirical evidence in humans. The neuroimaging data on 5-HT markers in abstinent recreational ecstasy/MDMA users are extensive and broadly consistent. Reduced levels of the 5-HT transporter (SERT) have been found by research groups worldwide using a variety of assessment measures. These SERT reductions occur across the higher brain regions and remain after controlling for potential confounds. There are also extensive empirical data for impairments in memory and higher cognition, with the neurocognitive deficits correlating with the extent of SERT loss. Hence, MDMA is clearly damaging to humans, with extensive empirical data for both structural and functional deficits.

Publication types

  • Comment

MeSH terms

  • Animals
  • Hallucinogens / adverse effects*
  • Humans
  • N-Methyl-3,4-methylenedioxyamphetamine / adverse effects*
  • Neurotoxicity Syndromes / etiology*

Substances

  • Hallucinogens
  • N-Methyl-3,4-methylenedioxyamphetamine